NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Azafaros

Azafaros

Private
LeidenHealthcare & Life Scienceshttps://www.azafaros.com/

Last Round

Series B

May 13, 2025

Total Funding Raised

$174.14M

Company Overview

Azafaros is a biopharmaceutical company developing disease-modifying therapeutics for rare lysosomal storage disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologyrare metabolic diseasessmall moleculelysosomal storage disordersorphan drugsblood-brain barrierclinical-stage biotechdrug discoveryGM2 gangliosidosisNiemann-Pick diseasebiopharmaclinical trialsdrug developmentmetabolic disordersCNS therapeutics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Azafaros Comps

Public and private peers based on sector, stage, and business model.

Azafaros comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Azafaros Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BMay 13, 2025
Series AFeb 6, 2020
SeedJul 23, 2018

Key People

Founding team and executive leadership

Stefano Portolano

Chief Executive Officer

Executive Team

Silvia Ragno

Chief Operating Officer

Executive Team

Azafaros Investors

Notable investors and investment history

Azafaros investors
InvestorRounds
Pictet GroupSeries B
Asahi Kasei Pharma Venture CapitalSeries B
BioMedPartnersSeries B, Series A
Asahi Kasei Therapeutics Venture CapitalSeries B
ForbionSeries B, Series A
Seroba Life SciencesSeries B
Forbion VenturesSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 8, 2026

    Will present at J.P. Morgan's 44th Annual Healthcare Conference.

  • Jun 9, 2025

    Will present at the BIO International Convention 2025.

Azafaros Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Azafaros Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Azafaros's valuation, stock price, and market status.

Firmographic Details

HeadquartersLeiden
Employee Range31
Year Founded2018
Last FundingMay 13, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.